S-Ethylisothiouronium diethylphosphate - TrioxBio
Alternative Names: Difetur; MTR 104; MTR-105; MTR-106; MTR-107; MTR-108; Nitric oxide synthase inhibitors - TrioxBio; Raviclust; Ravimig; RavitenLatest Information Update: 06 Jun 2018
Price :
$50 *
At a glance
- Originator Meditor Pharmaceuticals
- Developer TrioxBio
- Class Antihypotensives; Antimigraines; Phosphates; Urea compounds
- Mechanism of Action Nitric oxide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Hypotension
- Discontinued Intradialytic hypotension; Migraine
Most Recent Events
- 29 May 2018 MTR 107 receives Fast Track designation for Intradialytic hypotension [IV, Injection] in USA
- 29 May 2018 TrioxBio plans a phase II trial of MTR 107 for Intradialytic hypotension in USA in the fourth quarter of 2018
- 31 Dec 2017 TrioxBio plans a phase II trial of MTR 106 for migraine in the US and Europe (TrioxBio Website, May 2018).